|c‑Rel in Human PBMCs. c‑Rel was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using 15 µg/mL Rat Anti-Human c‑Rel Monoclonal Antibody (Catalog # MAB4606) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red; Catalog # NL013) and counterstained with nuclear stain (green). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.|
|Detection of Human c-Rel by Western Blot. Western blot shows lysates of K562 human chronic myelogenous leukemia cell line and Raji human Burkitt's lymphoma cell line. PVDF membrane was probed with 0.1 µg/mL of Rat Anti-Human c-Rel Monoclonal Antibody (Catalog # MAB4606) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for c-Rel at approximately 90 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.|
c-Rel/Rel, the cellular counterpart of the v-Rel oncogene of the avian reticuloendotheliosis retrovirus, is a 85 kDa class II member of the Rel/NK-kappa B family of transcription factors. All Rel family members contain a RHD (Rel homology domain) that is involved in dimerization, DNA and I kappa B binding, and nuclear localization. Class II members contain an additional C-terminal transcriptional activation segment. Rel both homodimerizes and heterodimerizes with multiple family members. Following dimerization, Rel complexes initiate transcription by acting on decameric DNA motifs termed kappa B binding sites. c-Rel activity is regulated by phosphorylation and ubiquitination. The important role of c-Rel in B-cell development, growth, and survival is well documented. c-Rel is also involved in responses to auto-antigens, allo-antigens, allergens and pathogens and may contribute to the development of certain human lymphoid cell cancers.